Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BetterLife Pharma ( (TSE:BETR) ) has issued an announcement.
BetterLife Pharma has granted 6,050,000 stock options to its directors, officers and employees, each exercisable at $0.055 per share over five years and vesting in four equal tranches from the grant date through 18 months. The move underscores the company’s use of equity-based incentives to align management and staff with long-term value creation as it advances BETR-001 through preclinical and IND-enabling studies and evaluates strategic options for its antiviral candidate.
The option grant may help BetterLife retain and motivate key personnel at a critical stage in its development pipeline, where progress on BETR-001 and potential monetization of its antiviral asset could shape future growth. By reinforcing internal incentives while holding a portfolio of patent-backed neurological and antiviral candidates, the company is positioning itself to compete in the emerging market for next-generation neuropsychiatric therapies and related therapeutics.
The most recent analyst rating on (TSE:BETR) stock is a Hold with a C$0.05 price target. To see the full list of analyst forecasts on BetterLife Pharma stock, see the TSE:BETR Stock Forecast page.
Spark’s Take on TSE:BETR Stock
According to Spark, TipRanks’ AI Analyst, TSE:BETR is a Neutral.
The score is held down primarily by weak financial fundamentals (no revenue, ongoing losses, and negative equity) and bearish technical trend signals. Improving TTM cash burn and a set of positive corporate updates provide some support, but valuation remains constrained by unprofitability and lack of dividend.
To see Spark’s full report on TSE:BETR stock, click here.
More about BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company developing and commercializing BETR-001, a proprietary non-hallucinogenic, non-controlled LSD derivative aimed at treating various neurological disorders. The preclinical candidate is designed to be self-administered and is supported by a synthesis patent and pending composition and method-of-use patents that could offer protection until around 2042, while the company also holds a separate antiviral drug asset under strategic review.
Average Trading Volume: 76,160
Technical Sentiment Signal: Sell
Current Market Cap: C$8.35M
See more data about BETR stock on TipRanks’ Stock Analysis page.